Anjli Kukreja currently serves as the Director of Translation and Biomarker Lead at Boehringer Ingelheim, where she leverages her extensive expertise in biochemistry and molecular biology to drive innovative solutions in drug discovery and development. With a strong foundation in various in vitro assay technologies,...
Anjli Kukreja currently serves as the Director of Translation and Biomarker Lead at Boehringer Ingelheim, where she leverages her extensive expertise in biochemistry and molecular biology to drive innovative solutions in drug discovery and development. With a strong foundation in various in vitro assay technologies, Anjli plays a pivotal role in advancing early-stage research, ensuring that critical biomarker strategies are effectively integrated into project pipelines. Her proficiency in cell culture, PCR, and qPCR allows her to develop and validate robust assays that are essential for biomarker identification and selection, which are crucial for understanding disease mechanisms and therapeutic responses.
At Boehringer Ingelheim, Anjli oversees key projects that span multiple therapeutic areas, focusing on the identification and validation of biomarkers that can guide clinical decision-making. Her collaborative approach fosters cross-functional partnerships, enabling her to provide comprehensive biomarker support throughout all stages of discovery and development. Anjli's experience in protein chemistry and virology further enhances her ability to navigate complex biological systems, making her an invaluable asset in the quest for novel therapeutics.
In her current role, she is particularly focused on developing biomarker plans that align with regulatory requirements and clinical objectives, ensuring that the translational aspects of research are seamlessly integrated into the broader development strategy. Anjli's solution-oriented mindset, combined with her deep understanding of the lifesciences landscape, positions her as a leader in the field, driving forward the mission of Boehringer Ingelheim to deliver innovative therapies that improve patient outcomes.
